Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation

  • Rolfo, Christian
  • Meshulami, Noy
  • Russo, Alessandro
  • Krammer, Florian
  • Garcia-Sastre, Adolfo
  • Mack, Philip C.
  • Gomez, Jorge E.
  • Bhardwaj, Nina
  • Benyounes, Amin
  • Moore, Amy
  • Rohs, Nicholas
  • Henschke, Claudia I.
  • Yankelevitz, David
  • King, Jennifer
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
[EN] Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%. The reasons for the increased vulnerability are not known. In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management.COVID-19 vaccines are safe and effective in people with lung cancer. On the basis of the available data, patients with lung cancer should continue their course of cancer treatment and get vaccinated against the SARS-CoV-2 virus. For unknown reasons, some patients with lung cancer mount poor antibody responses to vaccination. Thus, boosting vaccination seems urgently indicated in this subgroup of vulnerable patients with lung cancer. Nevertheless, many unanswered questions regarding vaccination in this population remain, including the magnitude, quality, and duration of antibody response and the role of innate and acquired cellular immunities for clinical protection. Additional important knowledge gaps also remain, including the following: how can we best protect patients with lung cancer from developing COVID-19, including managing care in patient with lung cancer and the home environment of patients with lung cancer; are there clinical/treatment demographics and tumor molecular demographics that affect severity of COVID-19 disease in patients with lung cancer; does anticancer treatment affect antibody production and protection; does SARS-CoV-2 infection affect the develop-ment/progression of lung cancer; and are special measures and vaccine strategies needed for patients with lung cancer as viral variants of concern emerge., Work in the Krammer laboratory on severe acute respiratory syndrome coronavirus 2. is supported by the National Institute of Allergy and Infectious Dis-eases Collaborative Influenza Vaccine Innovation Cen-ters contract 75N93019C00051, the Centers of Excellence for Influenza Research and Surveillance (contract #HHSN272201400008C) , the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 [5384]) , and anonymous donors. In addition, serology efforts in the Krammer laboratory are sup-ported by the National Cancer Institute SeroNet grant U54CA260560 and by the SeroNet in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract number 75N91019D00024, task order number 75N91021F00001. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Publication Artículo científico (JournalArticle)

Subcellular Localizations of RIG-I, TRIM25, and MAVS Complexes

  • Sánchez-Aparicio, M. T.
  • Ayllón Barasoain, Juan
  • Leo-Macias, A.
  • Wolff, T.
  • García Sastre, Adolfo
The retinoic acid-inducible gene 1 (RIG-I) signaling pathway is essential for the recognition of viruses and the initiation of host interferon (IFN)-mediated antiviral responses. Once activated, RIG-I interacts with polyubiquitin chains generated by TRIM25 and binds mitochondrial antiviral signaling protein (MAVS), leading to the production of type I IFN. We now show specific interactions among these key partners in the RLR pathway through the use of bimolecular fluorescence complementation (BiFC) and super-resolution microscopy. Dimers of RIG-I, TRIM25, and MAVS localize into different compartments. Upon activation, we show that TRIM25 is redistributed into cytoplasmic dots associated with stress granules, while RIG-I associates with TRIM25/stress granules and with mitochondrial MAVS. In addition, MAVS competes with TRIM25 for RIG-I binding, and this suggests that upon TRIM25-mediated activation of RIG-I, RIG-I moves away from TRIM25 to interact with MAVS at the mitochondria. For the first time, the distribution of these three proteins was analyzed at the same time in virus-infected cells. We also investigated how specific viral proteins modify some of the protein complexes in the pathway. The protease NS3/4A from hepatitis C virus redistributes the complexes RIG-I/MAVS and MAVS/MAVS but not RIG-I/TRIM25. In contrast, the influenza A virus NS1 protein interacts with RIG-I and TRIM25 in specific areas in the cell cytoplasm and inhibits the formation of TRIM25 homocomplexes but not the formation of RIG-I/TRIM25 heterocomplexes, preventing the formation of RIG-I/MAVS complexes. Thus, we have localized spatially in the cell different complexes formed between RIG-I, TRIM25, and MAVS, in the presence or absence of two viral IFN antagonistic proteins., We thank Peter Lichter (Heidelberg, Germany) for the BiFC plasmids and LuisMartinez-Sobrido for the HA-NS3/4A plasmids. We also acknowledge the help of theMicroscopy Shared Resource Facility at the Icahn School of Medicine at Mount Sinai,supported with funding from an NIH Shared Instrumentation Grant (1S10RR024745-01A1).This study was partly supported by the Center for Research on Influenza Pathogen-esis, the National Institute of Allergy and Infectious Disease (NIAID)-funded Center ofExcellence for Influenza Research and Surveillance (contract HHSN272201400008C), andby NIAID grant U19AI117873 (to A.G.-S.).